Assertio Holdings, Inc. (ASRT)
USD 0.62
(2.87%)
USD 0.62
(2.87%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 368.58 Million USD | -9.46% |
| 2022 | 79.39 Million USD | -6.23% |
| 2021 | 84.66 Million USD | -36.49% |
| 2020 | 133.32 Million USD | -39.6% |
| 2019 | 220.74 Million USD | -3.62% |
| 2018 | 229.03 Million USD | -32.05% |
| 2017 | 337.05 Million USD | -2.01% |
| 2016 | 343.97 Million USD | -3.14% |
| 2015 | 355.13 Million USD | 156.6% |
| 2014 | 138.4 Million USD | 17.49% |
| 2013 | 117.79 Million USD | 2.32% |
| 2012 | 115.13 Million USD | 19.02% |
| 2011 | 96.73 Million USD | 40.1% |
| 2010 | 69.04 Million USD | -7.38% |
| 2009 | 74.54 Million USD | 61.47% |
| 2008 | 46.16 Million USD | 198.86% |
| 2007 | 15.44 Million USD | -68.83% |
| 2006 | 49.55 Million USD | 65.15% |
| 2005 | 30 Million USD | 13.08% |
| 2004 | 26.53 Million USD | -12.65% |
| 2003 | 30.38 Million USD | 0.97% |
| 2002 | 30.08 Million USD | 67.21% |
| 2001 | 17.99 Million USD | 78.59% |
| 2000 | 10.07 Million USD | 61.24% |
| 1999 | 6.24 Million USD | 35.85% |
| 1998 | 4.6 Million USD | 119.05% |
| 1997 | 2.1 Million USD | 162.5% |
| 1996 | 800 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 19.15 Million USD | -21.77% |
| 2024 Q2 | 17.24 Million USD | 34.96% |
| 2023 FY | 71.88 Million USD | -9.46% |
| 2023 Q2 | 23.55 Million USD | 1.6% |
| 2023 Q3 | 32.5 Million USD | 37.98% |
| 2023 Q4 | 24.48 Million USD | -24.66% |
| 2023 Q1 | 23.18 Million USD | 5.99% |
| 2022 FY | 79.39 Million USD | -6.23% |
| 2022 Q4 | 21.87 Million USD | 10.11% |
| 2022 Q1 | 19.13 Million USD | -6.42% |
| 2022 Q2 | 18.51 Million USD | -3.28% |
| 2022 Q3 | 19.86 Million USD | 7.33% |
| 2021 Q2 | 33.45 Million USD | 134.31% |
| 2021 Q3 | 16.48 Million USD | -50.71% |
| 2021 Q4 | 20.45 Million USD | 24.04% |
| 2021 FY | 84.66 Million USD | -36.49% |
| 2021 Q1 | 14.27 Million USD | -49.1% |
| 2020 Q2 | 34.61 Million USD | -4.25% |
| 2020 Q3 | 32.64 Million USD | -5.67% |
| 2020 FY | 133.32 Million USD | -39.6% |
| 2020 Q1 | 36.15 Million USD | -33.01% |
| 2020 Q4 | 28.04 Million USD | -14.09% |
| 2019 Q4 | 53.96 Million USD | -14.39% |
| 2019 Q2 | 51.46 Million USD | -1.57% |
| 2019 Q3 | 63.03 Million USD | 22.49% |
| 2019 FY | 220.74 Million USD | -3.62% |
| 2019 Q1 | 52.28 Million USD | -1.57% |
| 2018 Q3 | 60.97 Million USD | 3.47% |
| 2018 FY | 229.03 Million USD | -32.05% |
| 2018 Q1 | 56 Million USD | -44.01% |
| 2018 Q2 | 58.93 Million USD | 5.23% |
| 2018 Q4 | 53.11 Million USD | -12.89% |
| 2017 Q4 | 100.01 Million USD | 31.01% |
| 2017 FY | 337.05 Million USD | -2.01% |
| 2017 Q1 | 79.33 Million USD | -4.81% |
| 2017 Q2 | 81.35 Million USD | 2.55% |
| 2017 Q3 | 76.34 Million USD | -6.16% |
| 2016 FY | 343.97 Million USD | -3.14% |
| 2016 Q4 | 83.35 Million USD | -6.37% |
| 2016 Q3 | 89.02 Million USD | 3.45% |
| 2016 Q2 | 86.05 Million USD | 0.6% |
| 2016 Q1 | 85.54 Million USD | -41.66% |
| 2015 Q2 | 88.85 Million USD | 128.18% |
| 2015 Q1 | 38.94 Million USD | 16.12% |
| 2015 Q3 | 80.7 Million USD | -9.17% |
| 2015 Q4 | 146.63 Million USD | 81.69% |
| 2015 FY | 355.13 Million USD | 156.6% |
| 2014 FY | 138.4 Million USD | 17.49% |
| 2014 Q4 | 33.53 Million USD | 7.26% |
| 2014 Q3 | 31.26 Million USD | -14.38% |
| 2014 Q2 | 36.51 Million USD | -1.58% |
| 2014 Q1 | 37.09 Million USD | 19.82% |
| 2013 FY | 117.79 Million USD | 2.32% |
| 2013 Q1 | 30.22 Million USD | 7.31% |
| 2013 Q3 | 28.87 Million USD | 4.07% |
| 2013 Q2 | 27.74 Million USD | -8.21% |
| 2013 Q4 | 30.96 Million USD | 7.24% |
| 2012 Q3 | 33.06 Million USD | 15.39% |
| 2012 Q1 | 25.25 Million USD | 3.84% |
| 2012 FY | 115.13 Million USD | 19.02% |
| 2012 Q4 | 28.16 Million USD | -14.81% |
| 2012 Q2 | 28.65 Million USD | 13.45% |
| 2011 Q1 | 22.65 Million USD | 22.4% |
| 2011 Q2 | 25.07 Million USD | 10.67% |
| 2011 Q4 | 24.32 Million USD | -1.47% |
| 2011 FY | 96.73 Million USD | 40.1% |
| 2011 Q3 | 24.68 Million USD | -1.56% |
| 2010 Q3 | 15.7 Million USD | -8.74% |
| 2010 Q1 | 17.61 Million USD | 14.99% |
| 2010 Q2 | 17.21 Million USD | -2.3% |
| 2010 Q4 | 18.51 Million USD | 17.85% |
| 2010 FY | 69.04 Million USD | -7.38% |
| 2009 FY | 74.54 Million USD | 61.47% |
| 2009 Q1 | 19.02 Million USD | 0.55% |
| 2009 Q2 | 19.96 Million USD | 4.97% |
| 2009 Q3 | 20.23 Million USD | 1.31% |
| 2009 Q4 | 15.32 Million USD | -24.27% |
| 2008 Q4 | 18.91 Million USD | 54.47% |
| 2008 Q3 | 12.24 Million USD | 405.91% |
| 2008 Q2 | 2.42 Million USD | -80.75% |
| 2008 Q1 | 12.57 Million USD | 162.85% |
| 2008 FY | 46.16 Million USD | 198.86% |
| 2007 Q4 | -20.01 Million USD | -343.83% |
| 2007 Q1 | 14.79 Million USD | 1.97% |
| 2007 FY | 15.44 Million USD | -68.83% |
| 2007 Q2 | 12.45 Million USD | -15.86% |
| 2007 Q3 | 8.2 Million USD | -34.09% |
| 2006 FY | 49.55 Million USD | 65.15% |
| 2006 Q3 | 13.76 Million USD | 17.98% |
| 2006 Q2 | 11.66 Million USD | 21.33% |
| 2006 Q1 | 9.61 Million USD | 41.37% |
| 2006 Q4 | 14.51 Million USD | 5.45% |
| 2005 FY | 30 Million USD | 13.08% |
| 2005 Q1 | 6.73 Million USD | 17.48% |
| 2005 Q2 | 8.26 Million USD | 22.83% |
| 2005 Q3 | 8.2 Million USD | -0.8% |
| 2005 Q4 | 6.8 Million USD | -17.09% |
| 2004 Q4 | 5.73 Million USD | -12.49% |
| 2004 Q1 | 6.71 Million USD | -29.19% |
| 2004 FY | 26.53 Million USD | -12.65% |
| 2004 Q2 | 7.53 Million USD | 12.17% |
| 2004 Q3 | 6.54 Million USD | -13.12% |
| 2003 Q3 | 7.22 Million USD | 1.21% |
| 2003 Q4 | 9.49 Million USD | 31.43% |
| 2003 Q2 | 7.13 Million USD | 9.17% |
| 2003 Q1 | 6.53 Million USD | -35.82% |
| 2003 FY | 30.38 Million USD | 0.97% |
| 2002 Q4 | 10.18 Million USD | 20.96% |
| 2002 FY | 30.08 Million USD | 67.21% |
| 2002 Q3 | 8.41 Million USD | 34.29% |
| 2002 Q2 | 6.26 Million USD | 20.15% |
| 2002 Q1 | 5.21 Million USD | 5.6% |
| 2001 Q3 | 4.96 Million USD | -59.71% |
| 2001 Q1 | 3.36 Million USD | 0.2% |
| 2001 FY | 17.99 Million USD | 78.59% |
| 2001 Q2 | 12.33 Million USD | 266.98% |
| 2001 Q4 | 4.94 Million USD | -0.56% |
| 2000 FY | 10.07 Million USD | 61.24% |
| 2000 Q4 | 3.35 Million USD | 38.82% |
| 2000 Q3 | 2.41 Million USD | 2.78% |
| 2000 Q1 | 1.95 Million USD | 11.78% |
| 2000 Q2 | 2.35 Million USD | 20.22% |
| 1999 FY | 6.24 Million USD | 35.85% |
| 1999 Q4 | 1.74 Million USD | 2.9% |
| 1999 Q2 | 1.4 Million USD | 0.0% |
| 1999 Q1 | 1.4 Million USD | -26.32% |
| 1999 Q3 | 1.7 Million USD | 21.43% |
| 1998 FY | 4.6 Million USD | 119.05% |
| 1998 Q2 | 900 Thousand USD | 12.5% |
| 1998 Q3 | 1 Million USD | 11.11% |
| 1998 Q4 | 1.9 Million USD | 90.0% |
| 1998 Q1 | 800 Thousand USD | 0.0% |
| 1997 Q3 | 400 Thousand USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q4 | 800 Thousand USD | 100.0% |
| 1997 FY | 2.1 Million USD | 162.5% |
| 1997 Q1 | - USD | 0.0% |
| 1996 FY | 800 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -4366.142% |
| Alpha Teknova, Inc. | 45.85 Million USD | -703.735% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -88.07% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -721.744% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -131.512% |
| Cosmos Health Inc. | 26.18 Million USD | -1307.845% |
| Journey Medical Corporation | 54.59 Million USD | -575.138% |
| Embecta Corp. | 528.4 Million USD | 30.245% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -35.561% |
| Dynavax Technologies Corporation | 219.14 Million USD | -68.192% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 37.529% |
| Pacira BioSciences, Inc. | 326.37 Million USD | -12.932% |
| PainReform Ltd. | 9.58 Million USD | -3745.837% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -2708.38% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -2708.38% |
| SCYNEXIS, Inc. | 51.84 Million USD | -610.895% |
| Safety Shot Inc | 12.1 Million USD | -2943.719% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -11909.202% |
| Procaps Group, S.A. | 199.47 Million USD | -84.776% |
| Theratechnologies Inc. | 72.75 Million USD | -406.604% |
| Harrow Health, Inc. | 89.97 Million USD | -309.662% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -3802.022% |
| Biofrontera Inc. | 39.95 Million USD | -822.408% |
| DURECT Corporation | 43.71 Million USD | -743.155% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 30.326% |
| Cronos Group Inc. | 96.7 Million USD | -281.128% |
| OptiNose, Inc. | 85.1 Million USD | -333.11% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -58.788% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -841.397% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 3955.088% |
| Organogenesis Holdings Inc. | 314.13 Million USD | -17.334% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -3687.805% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -756.367% |
| Radius Health, Inc. | 265.92 Million USD | -38.603% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -2562.819% |
| ProPhase Labs, Inc. | 37.85 Million USD | -873.753% |
| Phibro Animal Health Corporation | 260.29 Million USD | -41.601% |
| Procaps Group S.A. | 187.24 Million USD | -96.846% |
| Alvotech | 285.43 Million USD | -29.13% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -3651.501% |
| Viatris Inc. | 5.96 Billion USD | 93.822% |
| Rockwell Medical, Inc. | 15.37 Million USD | -2297.457% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -515.951% |
| SIGA Technologies, Inc. | 22.04 Million USD | -1572.116% |
| Tilray Brands, Inc. | 251.35 Million USD | -46.638% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -651.631% |
| Shineco, Inc. | 17.94 Million USD | -1953.623% |
| PetIQ, Inc. | 192.72 Million USD | -91.249% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -9135.085% |
| Incannex Healthcare Limited | 30.05 Million USD | -1126.45% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 76.913% |
| Alimera Sciences, Inc. | 62.64 Million USD | -488.409% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -48239.524% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -6162.519% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1969.71% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -1641.155% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1651.655% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -123.431% |
| Hempacco Co., Inc. | 7.59 Million USD | -4752.07% |
| Talphera, Inc. | 11.99 Million USD | -2973.078% |
| Alvotech | 285.43 Million USD | -29.13% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -161.939% |
| Lantheus Holdings, Inc. | 344.9 Million USD | -6.867% |
| Currenc Group, Inc. | 24 Million USD | -1435.637% |
| Kamada Ltd. | 45.42 Million USD | -711.397% |
| Indivior PLC | 911 Million USD | 59.541% |
| Evoke Pharma, Inc. | 12.4 Million USD | -2870.15% |
| Flora Growth Corp. | 10.57 Million USD | -3384.119% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1651.655% |
| Evolus, Inc. | 189.75 Million USD | -94.238% |
| HUTCHMED (China) Limited | 436.23 Million USD | 15.507% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -139.133% |
| Akanda Corp. | 3.48 Million USD | -10480.857% |